EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preclinical Study on the Long-Term Efficacy and Safety of Sustained-Release Gas6 Liposomes Combined With MERTK Gene Therapy for Retinitis Pigmentosa

Shen Wu, Yingyan Mao, Xuejing Yan, Qian Liu, Yufei Teng, Jingxue Zhang

Translational Vision Science & Technology · 2025

DOI: 10.1167/tvst.14.12.19 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2025. Verfasst von Shen Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Key Laboratory of Intelligent Diagnosis Technology …. Hauptthemen laut MEDLINE: Genetic Therapy, c-Mer Tyrosine Kinase, Retinitis Pigmentosa, Intercellular Signaling Peptides and Proteins. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Our previous studies in Royal College of Surgeons (RCS) rats demonstrated that co-administration of MER proto-oncogene tyrosine kinase (MERTK) and its ligand Gas6 effectively protected photoreceptors and improved visual function. To facilitate clinical translation, we developed Gas6-loaded sustained-release liposomes (Gas6 Lips) using liposomes with superior biocompatibility and enhanced release stability as the delivery vehicle, and subsequently evaluated their long-term efficacy and safety in RCS rats and nonhuman primates.

Methods

Gas6 Lips were synthesized using a thin-film hydration method and characterized for morphology, encapsulation efficiency, and release profile. A GMP-grade adeno-associated virus serotype 2 (AAV2)-BEST1-hMERTK vector was constructed. Experimental groups included the AAV-hMERTK group, the combination group with AAV-hMERTK and Gas6 Lips, and the control group. Therapeutic efficacy was assessed in RCS rats using electroretinography (ERG) and histological analysis. Long-term safety was evaluated in cynomolgus monkeys over 12 months.

Results

Gas6 Lips had an average size of 144.1 nm and sustained Gas6 release for over 5 weeks. In RCS rats, the combination group exhibited significantly higher ERG b-wave amplitudes (52.116 ± 9.747 µV vs. 36.186 ± 7.156 µV, P < 0.01) and greater outer nuclear layer preservation (14.47 ± 1.43 µm vs. 10.41 ± 1.19 µm, P < 0.01) compared with the AAV-hMERTK group. These therapeutic effects persisted for over 7 weeks. In primates, no significant changes in retinal structure, ERG, or systemic immune responses were observed, with only transient and reversible mild ocular inflammation in the early post-treatment phase.

Conclusions

Gas6 Lips combined with AAV2-BEST1-hMERTK effectively preserved retinal structure and function in RCS rats and demonstrated long-term safety in primates, supporting its potential for clinical translation. Translational Relevance: This can provide preclinical efficacy and safety data for the clinical translation of Gas6 Lips for the treatment of retinal pigmentosa (RP).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Therapyc-Mer Tyrosine KinaseRetinitis PigmentosaIntercellular Signaling Peptides and ProteinsAnimalsLiposomesRatsMacaca fascicularisProto-Oncogene MasDelayed-Action PreparationsElectroretinographyMaleDisease Models, AnimalGrowth Arrest-Specific Protein 6

Substanzen

Liposomesc-Mer Tyrosine KinaseIntercellular Signaling Peptides and ProteinsProto-Oncogene MasDelayed-Action PreparationsGrowth Arrest-Specific Protein 6MAS1 protein, human

Autor:innen und Institutionen

  • Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Key Laboratory of Intelligent Diagnosis Technology and Equipment for Optic Nerve-Related Eye Diseases, Capital Medical Un…
  • Henan Academy of Innovations in Medical Science, Zhengzhou, People's Republic of China.

Zitieren

APA

Wu, S., Mao, Y., Yan, X., Liu, Q., Teng, Y., & Zhang, J. (2025). Preclinical Study on the Long-Term Efficacy and Safety of Sustained-Release Gas6 Liposomes Combined With MERTK Gene Therapy for Retinitis Pigmentosa. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.14.12.19

Vancouver

Wu S, Mao Y, Yan X, Liu Q, Teng Y, Zhang J. Preclinical Study on the Long-Term Efficacy and Safety of Sustained-Release Gas6 Liposomes Combined With MERTK Gene Therapy for Retinitis Pigmentosa. Translational Vision Science & Technology. 2025. doi:10.1167/tvst.14.12.19

BibTeX
@article{Wu2025,
  author = {Wu, Shen and Mao, Yingyan and Yan, Xuejing and Liu, Qian and Teng, Yufei and Zhang, Jingxue},
  title = {Preclinical Study on the Long-Term Efficacy and Safety of Sustained-Release Gas6 Liposomes Combined With MERTK Gene Therapy for Retinitis Pigmentosa},
  journal = {Translational Vision Science & Technology},
  year = {2025},
  doi = {10.1167/tvst.14.12.19}
}
Kostenlos starten →